A small side benefit of having 30% in immunotherapies, while it is being funded with $18m, is that as our third pillar, it keeps AHZ a little more complex.
Clearly AHZ has the potential to be $10 in 5 years. However, biotech / medtech is an industry sector rife with takeovers. The more complex (and higher market cap / PE ratio) the less palatable we are for an opportunistic $1 or $2 takeover.
A small side benefit of having 30% in immunotherapies, while it...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.55 |
Change
-0.130(1.11%) |
Mkt cap ! $244.1M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.89 | $11.41 | $703.3K | 60.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $11.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.83 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |